• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依诺肝素与持续静脉输注肝素用于心房颤动合并晚期慢性肾脏病患者围手术期桥接治疗的比较

Enoxaparin vs Continuous Heparin for Periprocedural Bridging in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.

作者信息

Schexnayder Chandler David, Aguilar Christine, Morneau Kathleen

机构信息

is a Home-Based Primary Care Clinical Pharmacy Specialist, and is an Inpatient Surgery Clinical Pharmacy Specialist, both at the Michael E. DeBakey VA Medical Center in Houston, Texas. is a Clinical Pharmacy Specialist in the Medical Intensive Care Unit and Antimicrobial Stewardship at the Audie L. Murphy Veterans Hospital in San Antonio, Texas.

出版信息

Fed Pract. 2019 Jul;36(7):306-315.

PMID:31384119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6654170/
Abstract

Bridging with enoxaparin rather than heparin has the potential to reduce the length of hospital stay, incidence of nosocomial infections, and cost of hospitalization.

摘要

与依诺肝素而非肝素桥接有可能缩短住院时间、降低医院感染发生率并降低住院费用。

相似文献

1
Enoxaparin vs Continuous Heparin for Periprocedural Bridging in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.依诺肝素与持续静脉输注肝素用于心房颤动合并晚期慢性肾脏病患者围手术期桥接治疗的比较
Fed Pract. 2019 Jul;36(7):306-315.
2
Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).在接受经食管超声心动图引导下心脏复律的心房颤动患者中，使用依诺肝素与普通肝素的费用比较（来自经食管超声心动图评估心脏复律[ACUTE] II随机多中心研究）。
Am J Cardiol. 2008 Feb 1;101(3):338-42. doi: 10.1016/j.amjcard.2007.09.075.
3
Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.机械心脏瓣膜患者与非瓣膜性心房颤动患者皮下注射依诺肝素作为门诊抗凝桥接治疗的安全性比较。
Am J Cardiol. 2009 Nov 15;104(10):1429-33. doi: 10.1016/j.amjcard.2009.06.065. Epub 2009 Sep 26.
4
Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?心脏手术后桥接治疗中低剂量依诺肝素与高剂量依诺肝素的比较：哪种剂量方案更优？
Clin Hemorheol Microcirc. 2013 Jan 1;54(3):249-58. doi: 10.3233/CH-131731.
5
Health status outcomes after cardioversion for atrial fibrillation: results from the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Trial.心房颤动复律后的健康状况结局：经食管超声心动图评估复律（ACUTE）II试验的结果
Am Heart J. 2008 Aug;156(2):374.e1-6. doi: 10.1016/j.ahj.2008.05.008.
6
Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.在经食管超声心动图引导下房颤复律中使用依诺肝素与普通肝素的抗凝和抗炎反应比较。
Am J Cardiol. 2008 Oct 1;102(7):842-6. doi: 10.1016/j.amjcard.2008.05.025. Epub 2008 Jul 9.
7
Continuous warfarin therapy is safe and feasible in catheter ablation of atrial fibrillation.持续性华法林治疗在房颤导管消融中是安全且可行的。
Scand Cardiovasc J. 2013 Apr;47(2):109-13. doi: 10.3109/14017431.2012.743674. Epub 2012 Nov 27.
8
Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.低分子量肝素与普通肝素作为心房颤动所致栓塞性卒中患者桥接治疗的疗效、安全性及耐受性研究
J Vasc Interv Neurol. 2016 Jun;9(1):35-41.
9
Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study.经食管超声心动图指导下依诺肝素抗栓策略用于心房颤动复律：ACUTE II 初步研究
Am Heart J. 2000 Jun;139(6):E1-7. doi: 10.1067/mhj.2000.106628.
10
Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis.需要暂时中断抗凝治疗的房颤患者围手术期肝素桥接治疗：来自荟萃分析的证据
J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2215-21. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.006. Epub 2016 Jun 8.

本文引用的文献

1
2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.2017 年美国心脏病学会专家共识决策路径：非瓣膜性心房颤动患者抗凝治疗围术期管理：美国心脏病学会临床专家共识文件工作组的报告。
J Am Coll Cardiol. 2017 Feb 21;69(7):871-898. doi: 10.1016/j.jacc.2016.11.024. Epub 2017 Jan 9.
2
Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages.中风与慢性肾脏病：不同肾病阶段的流行病学、发病机制及管理
Semin Nephrol. 2015 Jul;35(4):311-22. doi: 10.1016/j.semnephrol.2015.06.003.
3
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.心房颤动患者围手术期的桥接抗凝治疗
N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.
4
Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).心房颤动患者抗凝治疗中断期间桥接治疗的使用情况及相关结局：心房颤动更明智治疗结局登记研究（ORBIT-AF）的结果
Circulation. 2015 Feb 3;131(5):488-94. doi: 10.1161/CIRCULATIONAHA.114.011777. Epub 2014 Dec 12.
5
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.KDIGO 美国评论：2012 年 KDIGO 慢性肾脏病评估与管理临床实践指南
Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16.
6
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.抗栓治疗的围手术期管理：抗栓治疗与血栓预防，第 9 版：美国胸科医师学会循证临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e326S-e350S. doi: 10.1378/chest.11-2298.
7
Dosing low molecular weight heparins in kidney disease.肾病患者中低分子量肝素的给药
J Pharm Pract. 2010 Jun;23(3):205-9. doi: 10.1177/0897190010362175. Epub 2010 Apr 7.
8
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.经皮冠状动脉介入治疗中抗栓治疗的发生率、预后影响以及对入路和非入路部位出血的影响。
JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011.
9
Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.房颤患者中依诺肝素桥接慢性口服抗凝治疗：前瞻性 BRAVE 注册研究结果。
Cardiovasc Ther. 2009 Winter;27(4):230-8. doi: 10.1111/j.1755-5922.2009.00099.x.
10
Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.慢性肾脏病与静脉血栓栓塞症：流行病学及发病机制
Curr Opin Pulm Med. 2009 Sep;15(5):408-12. doi: 10.1097/MCP.0b013e32832ee371.